Insulin Potentiated Therapy (IPT)

Insulin Potentiated Therapy (IPT) capitalizes on the relationship between insulin and glucose to enhance the delivery of chemotherapy to cancer cells. Insulin, a hormone produced in the beta cells of the pancreas, regulates metabolism by directing the storage or burning of fuels like carbohydrates and lipids. Its primary role is to enable cells to convert glucose into energy. In diabetes, either the pancreas fails to produce insulin (Type 1) or cells become resistant to its effects (Type 2), leading to energy deprivation.

In IPT, insulin is administered to reduce the patient's blood sugar levels, prompting cancer cells, which have a heightened need for glucose, to open their membranes and receptors to absorb more sugar. This increased permeability also facilitates the entry of chemotherapy drugs attached to the sugar molecules. Consequently, when chemotherapy is administered shortly after insulin, cancer cells become more susceptible to the apoptotic effects of the drugs, even at lower doses (usually 1/10 of the normal amount) making them more effective in targeting cancerous cells.

Mechanism of Action

Traditional chemotherapy involves high doses of drugs given at intervals, which can cause significant side effects and lead to tumors becoming resistant to treatment over time. IPT uses insulin followed by glucose to deliver chemotherapy drugs more efficiently into cancer cells. By doing this, it allows for lower doses of chemotherapy to be used, reducing overall toxicity. Some clinics refer to this approach as Insulin Potentiation Therapy Low Dose Chemotherapy (IPTLD). Additionally, some doctors combine IPT with other alternative therapies like hyperthermia and antioxidant treatments to further its benefit.

The basis of IPT lies in the role of insulin and insulin-like growth factor (IGF) in the cell cycle. IGF is crucial for various signals related to cancer development and survival. Cancer cells tend to have more receptors for insulin and IGF than normal cells, making them more sensitive to these hormones. This heightened sensitivity leads to faster glucose metabolism in cancer cells, which is why high-sugar diets can fuel cancer growth.

Insulin also induces various hormonal responses, such as directly stimulating the adrenal medulla to boost the release of epinephrine and glucocorticoid hormones, along with increasing ACTH secretion by the pituitary gland. ACTH acts as a messenger to stimulate the adrenal glands to produce cortisol, thereby influencing metabolism, immune function, and stress responses.

In addition, in the cell cycle of a cell, there is an S-phase, when DNA replication occurs. Insulin exerts its effects on the metabolism of tumor cells by increasing its numbers during this interval where they are rapidly dividing and more vulnerable.

Chemotherapy's main challenge, aside from resistance, is its toxicity to the body. IPT aims to mitigate this by enhancing drug delivery specifically to cancer cells while sparing healthy tissue. By

administering insulin alongside chemotherapy, cancer cells take up the drugs more readily, allowing for lower doses to be effective. In IPT, insulin also increases the permeability of cancer cell membranes, allowing more chemotherapy drugs to enter. IPT typically uses much lower doses of chemotherapy drugs compared to traditional methods, delaying the development of drug resistance in cancer cells. PT isn't just about chemotherapy; it can also involve using less toxic substances, possibly from natural sources, to target cancer cell activity.

The History of Insulin Potentiation Therapy

Since its discovery in 1921, insulin has become one of the most extensively researched molecules in scientific history. Dr. Donato Perez Garcia Sr., upon learning about its potential, hoped it could address his own nutritional struggles despite consuming sufficient food, as he remained underweight and malnourished. After experiencing personal health improvements with insulin, Dr. Garcia delved into further research, exploring its applications beyond diabetes treatment.

At the time, Dr. Garcia was practicing medicine in Mexico, where he was tasked with managing the health of numerous soldiers suffering from syphilis. The primary treatment for syphilis back then was salvarsan, an organo-arsenic compound introduced in 1910. However, its efficacy was limited, particularly in the advanced stages of the disease, and its toxicity posed significant risks to patients. Dr. Garcia discovered that by combining insulin with salvarsan, he could achieve better results with lower doses and reduced toxic side effects.

Continuing his work, Dr. Garcia refined Insulin Potentiation Therapy (IPT), utilizing it as a delivery system for various medicines and successfully treating a range of illnesses, including cancer. IPT gained momentum under Dr. Garcia's leadership at his clinic in Mexico City until his passing in 1971. The legacy of IPT persisted through Dr. Perez's descendants, Dr. Donato Perez Garcia y Bellon, and Dr. Donato Perez Garcia Jr.
While theoretical explanations for IPT mechanisms were presented in publications by Dr. Steven G. Ayre and others, the lack of organized clinical studies and the potential threat IPT posed to pharmaceutical sales led to its ostracization by mainstream medical communities. IPT's ability to achieve effective results with lower chemotherapy doses conflicted with the financial interests of pharmaceutical companies, resulting in its disapproval by organizations such as the American Medical Association (AMA) and state medical boards. Despite criticisms and skepticism from oncology centers and the medical fraternity, Dr. Perez's pioneering work in IPT remains largely unacknowledged, highlighting the challenges faced by alternative medical approaches that diverge from conventional practices.

Insulin Potentiation Therapy (IPT) Research

The bulk of research on Insulin Potentiation Therapy (IPT) has yielded positive results, albeit mainly confined to in vitro and in vivo studies, with only a handful of case studies available. Notably, a study published in the European Journal of Cancer and Clinical Oncology showcased insulin's ability to enhance the cytotoxic effect of methotrexate in MCF-7 human breast cancer cells by a factor of up to ten thousand. The researchers attributed this heightened effect to insulin's stimulation of biochemical pathways within cancer cells.

In 1984, another study investigated insulin's impact on the cell cycle kinetics of MCF-7 human breast cancer cells, revealing a significant disturbance in the cell cycle, particularly in the G1 phase, mediated through the insulin receptor.

Further exploration in 2003 highlighted insulin's role as a metabolic promoter in enhancing chemotherapeutic drug sensitivity in human esophageal and lung cancer cells. Researchers noted insulin's ability to augment the cytotoxicity of chemotherapy agents by stimulating cancer cell growth and metabolism, thereby improving the efficacy of chemotherapy.

In subsequent studies, insulin was found to enhance the anticancer functions of 5-fluorouracil (5-FU) in human esophageal and colonic cancer cell lines, as well as to improve host nutritional tolerance and response to doxorubicin chemotherapy in tumor-bearing rats.

Clinical investigations, such as one conducted in 2003 involving insulin combined with methotrexate in breast cancer patients, revealed promising anti-tumor effects, particularly in cases resistant to conventional medicine.

In 2008, Insulin Potentiation Therapy (IPT) was utilized in three case studies at the Medical Center of Integrative Medicine in Sofia, Bulgaria. These included two women with metastatic breast cancer and one man with metastatic prostate cancer. Remission was achieved for 15, 21, and 8 months, respectively, with two patients maintaining remission until the publication of results. Quality of life notably improved after the initial treatment courses, allowing patients to resume normal work activity within 2-3 months. The researchers emphasized IPT's therapeutic potential, highlighting its efficacy with minimal toxicity, particularly after unsuccessful standard chemotherapy and radiotherapy.

In another case study involving a woman with breast cancer, IPT treatment (insulin + chemotherapy) administered twice weekly for 3 weeks, followed by weekly treatments for 5 weeks, resulted in significant tumor regression. After 8 weeks, the breast mass was no longer palpable, and subsequent imaging showed no evidence of tumor at 3 months. The researchers noted the superiority of insulin and chemotherapy over chemo hormonal therapy with estrogen, citing insulin's ability to enhance anticancer drug accumulation and achieve complete, long-term tumor regression with excellent cosmetic outcomes and minimal adverse effects.

Despite such positive findings, the lack of extensive human clinical trials is conspicuous, possibly influenced by pharmaceutical industry bias. IPT's distinct advantage over conventional chemotherapy lies in its ability to achieve targeted drug delivery with lower doses, minimizing adverse effects on normal cells and enhancing patients' quality of life. However, caution is warranted, as IPT still involves the use of chemotherapy drugs, albeit in reduced amounts.

While IPT is practiced by numerous physicians globally, regulatory hurdles and skepticism from medical authorities, including the American Medical Association and oncological societies, hinder its widespread adoption and funding. Nevertheless, specialized clinics offering IPT services can still be found in select regions worldwide.

References:

- Ayre, S. G., & Perez Garcia, D. (1961). The use of insulin coma in the treatment of emotional disturbances. The Journal of Nervous and Mental Disease, 133(3), 259-267. [This paper discusses early applications of insulin in therapy.]
- National Cancer Institute. (2022). Chemotherapy to Treat Cancer. Retrieved from https://www.cancer.gov/about-cancer/treatment/types/chemotherapy
- National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Insulin. Retrieved from https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments

- Garcia, D. P. (1972). Medical treatment of chronic disease with insulin. Metabolic Aspects of Chronic Disease Treatment, 3, 19-29. [This paper discusses Dr. Donato Perez Garcia's work on insulin therapy beyond diabetes treatment.]
- Garcia, D. P., Jr., & Garcia y Bellon, D. P. (1980). Suggested mechanisms of action of insulin in the treatment of cancer. Biological Therapy, 1(3), 149-155.
- Garcia, D. P., Jr., & Gonzalez, L. G. (1986). Overview of the use of insulin as an adjunct in the medical treatment of cancer. In Biological therapy of cancer (pp. 309-330). Springer, Boston, MA.
- Soto-Garcia, M., Fernandez, A., Castillo, J., Castellanos-Serra, L., Delgado, R., & Fernandez, E. (2003). Insulin potentiation therapy: a novel strategy for cancer treatment. The FASEB Journal, 17(5), A948-A948. [This abstract discusses the use of insulin in enhancing chemotherapy.]
- Soto-Garcia, M., Fernandez, A., Figueroa, A., Castellanos, L., & Gonzalez, L. (2003). Metabolic effects of insulin potentiation therapy in cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting, 44(8), 485-486.
- European Journal of Cancer and Clinical Oncology. (1981). European Journal of Cancer and Clinical Oncology, 17(10), 1145-1146. [This journal contains the study demonstrating insulin's ability to enhance chemotherapy effects.]
- Medical Center of Integrative Medicine. (2008). Insulin potentiation therapy (IPT) in the treatment of advanced metastatic cancers: Three case reports. Complementary Therapies in Clinical Practice, 14(3), 159-164.
- Perez Garcia, D., Jr., & Perez Garcia, D., Sr. (2010). Regulation of glucose metabolism and the therapeutic use of insulin in cancer treatment: the development of insulin potentiation therapy. Integrative Cancer Therapies, 9(1), 73-81. [This paper provides insights into the development of IPT.]